Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
US7670855B2 · kind B2 · utility
3Cited by
12References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 27, 2007 |
| Grant date | Mar 2, 2010 |
| Priority date | — |
| Expiry date | Aug 5, 2027 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/825
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit Chlamydia-neutralizing antibodies. The invention also features methods for induction of a protective immune response against infection by Chlamydia and Chlamydiophila.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.